N/A
Completed N=167
Oral vs. Intravenous TXA Study Proposal: TJA
Blood Loss After Primary Total Joint Arthroplasty · Need for Blood Transfusion After Total Joint Arthroplasty
Source: ClinicalTrials.gov NCT02233101 ↗
Enrolled (actual)
167
Serious AEs
0.0%
Results posted
Apr 2017
Primary outcomePrimary: Number of Participants Who Required Blood Transfusion — 4; 2 participants
Summary
Purpose: Examine oral and intravenous Tranexamic Acid (TXA) to determine whether or not the different routes of drug administration are equivalent in terms of post-operative reduction in hemoglobin, number of transfusions, and post-operative blood loss following TJA surgery.
Hypothesis: Oral and intravenous TXA are equivalent routes of drug administration.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Number of Participants Who Required Blood Transfusion |
4; 2 | — |
| SECONDARY Other Complications |
0; 0 | — |
Eligibility Criteria
Inclusion Criteria
- Any patient scheduled for a primary TKA or cementless THA with epidural/spinal anesthesia
Exclusion Criteria
- Allergy to TXA, acquired disturbances of color vision, refusal of blood products, pre-op use of anticoagulant therapy within five days before surgery, a history of arterial or venous thromboembolic disease (such as DVT, PE, CVA, TIA), pregnancy, breastfeeding, major comorbidities (such as severe ischemic heart disease [New York Heart Association Class III or IV], previous myocardial infarction, severe pulmonary disease, renal impairment, or hepatic failure), patients who decline to participate, any patient undergoing a revision TKA, THA or BHR
Data sourced from ClinicalTrials.gov (NCT02233101). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.